Group antenatal care for improving retention of adolescent and young pregnant women living with HIV in Kenya

Teasdale, Chloe A.; Odondi, Judith; Kidiga, Catherine; Choy, Michelle; Fayorsey, Ruby; Ngeno, Bernadette; Ochanda, Boniface; Langat, Agnes; Ngugi, Catherine; Callahan, Tegan; Modi, Surbhi; Hawken, Mark; Odera, Doris; Abrams, Elaine J.

doi:10.1186/s12884-022-04527-z

BMC Pregnancy and Childbirth

Table 1 Characteristics of pregnant adolescent and young women living with HIV (AYWLH) < 25 years of age newly enrolled in antenatal (ANC) services with antiretroviral therapy (ART) start date at seven HOPE project facilities in Kenya in the pre- and post-periods (N = 543)

From: Group antenatal care for improving retention of adolescent and young pregnant women living with HIV in Kenya

	Pre-period AYWLH newly enrolled ANC Jan-Dec 2016						Post-period (All) AYWLH newly enrolled ANC Dec 2017-Jan 2019						Pre- vs. post-period	Post-period (HOPE attendees) AYWLH newly enrolled ANC Dec 2017-Jan 2019						Pre- vs. post-period
	< 20 years		20–24 years		All		< 20 years		20–24 years		All		Pre- vs. post-period	< 20 years		20–24 years		All		Pre- vs. post-period
	N	%	N	%	N	%	N	%	N	%	N	%	p-value	N	%	N	%	N	%	p-value
	47	21.1	176	78.9	223	100.0	53	16.6	267	83.4	320	100.0		46	18.0	209	82.0	255	100.0
Gestational age weeks, median (IQR)	22 (16–29)		22 (16–26)		22 (16–26)		22 (14–28)		20 (14–26)		20 (14–26)		0.11	24 (14–28)		20 (13–26)		20 (13–26)		0.16
Trimester														12	26.1	57	27.3	69	27.1
1st	9	19.2	31	17.7	40	18.0	15	28.3	69	25.8	84	26.3	0.06	20	43.5	108	51.7	128	50.2	0.05
2nd	22	46.8	109	62.3	131	59.0	24	45.3	139	52.1	163	50.9		14	30.4	44	21.1	58	22.8
3rd	16	34.0	35	20.0	51	23.0	14	26.4	59	22.1	73	22.8
Parity*
0	30	63.8	34	19.3	64	28.7	41	77.4	84	31.6	125	39.2	0.06	35	76.1	73	35.1	108	42.5	0.03
1–3	17	36.2	137	77.8	154	69.1	12	22.6	180	67.7	192	60.2		11	23.9	133	63.9	144	56.7
> 3	0	0.0	5	2.8	5	2.2	0	0.0	2	0.8	2	0.6		0	0.0	2	1.0	2	0.8
Married (reported)*	30	63.8	152	86.4	182	81.6	32	60.4	214	80.2	246	76.9	0.20	28	60.9	163	78.0	191	74.9	0.10
HIV status at entry to ANC*
Newly diagnosed	32	68.1	81	46.0	113	50.7	26	49.1	93	34.8	119	37.2	< 0.001	22	47.8	77	36.8	99	38.8	< 0.01
Known HIV-positive	15	31.9	95	54.0	110	49.3	27	50.9	174	65.2	201	62.8		24	52.2	132	63.2	156	61.2
ART status from ANC register
On ART at first ANC	11	23.4	57	32.4	68	30.5	20	37.7	142	53.2	162	50.6	< 0.0001	17	37.0	112	53.6	129	50.6	< 0.0001
Started ART first ANC (≤ 7 days)	29	61.7	90	51.1	119	53.4	30	56.6	102	38.2	132	41.3		26	56.5	81	38.8	107	42.0
Started ART > 7 days firs ANC	7	14.9	29	16.5	36	16.1	3	5.7	23	8.6	26	8.1		3	6.5	16	7.7	19	7.4
First ART regimen
TDF + 3TC + EFV	46	97.9	150	85.2	196	87.9	48	90.6	247	92.5	295	92.2	0.08	41	89.1	191	91.4	232	91.0	0.39
Other	1	2.1	26	14.8	27	12.1	5	9.4	20	7.5	25	7.8		5	10.9	18	8.6	23	9.0
Attended at least one HOPE visit							46	86.8	209	78.3	255	79.7		46	100.0	209	100.0	255	100.0
Median number of visits (IQR)							5 (4–8)		7 (5–9)		7 (5–9)			5 (4–8)		7 (5–9)		7 (5–9)

^* Age group differences within period (pre and post) statistically significant p < 0.05
TDF tenofovir, 3TC Lamivudine, EFV Efavirenz

Back to article page

ISSN: 1471-2393

Contact us

Submission enquiries: bmcpregnancyandchildbirth@biomedcentral.com
General enquiries: ORSupport@springernature.com